Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when
given together with sirolimus and to see how well they work in treating patients with
recurrent malignant glioma.